Related Experiment Video
Updated: Aug 2, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 19, 2013
Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation
1Department of Infectious Diseases, Nagoya University Graduate School of Medicine, Nagoya, Japan. kiyoi@med.nagoya-u.ac.jp
Abstract:
Overexpression and activating mutations of receptor tyrosine kinases (RTKs) are known to be involved in the pathophysiology of several kinds of cancer cells. FMS-like receptor tyrosine kinase 3 (FLT3), together with KIT, FMS, and platelet-derived growth factor receptor, is a class III RTK. FLT3 mutations were first reported as internal tandem duplication (FLT3/ITD) of the juxtamembrane domain-coding sequence; subsequently, a missense point mutation at the D835 residue and point mutations, deletions, and insertions in the codons surrounding D835 within a FLT3 tyrosine kinase domain (FLT3/KDMs) have been found. FLT3 mutations are the most frequent genetic alterations so far reported in acute myeloid leukemia and are involved in the signaling pathway of autonomous proliferation and differentiation block in leukemia cells. Several large-scale studies have confirmed that FLT3/ITD is strongly associated with leukocytosis and a poor prognosis. Therefore, routine screening for FLT3 mutations is recommended to stratify patients into distinct risk groups. However, because high-dose chemotherapy and stem cell transplantation cannot overcome the adverse effects of FLT3 mutations, the development of FLT3 kinase inhibitors is expected to produce a more efficacious therapeutic strategy for leukemia therapy.
Insights
FMS-like receptor tyrosine kinase 3 (FLT3) mutations are common in acute myeloid leukemia and linked to poor prognosis. Developing FLT3 kinase inhibitors offers a promising therapeutic strategy for leukemia patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Receptor tyrosine kinases (RTKs) and their mutations are implicated in cancer development.
- FMS-like receptor tyrosine kinase 3 (FLT3) is a class III RTK frequently altered in cancer.
- FLT3 mutations, including internal tandem duplications (FLT3/ITD) and tyrosine kinase domain mutations (FLT3/KDMs), are prevalent in acute myeloid leukemia (AML).
Purpose of the Study:
- To summarize the role of FLT3 mutations in acute myeloid leukemia.
- To highlight the prognostic significance of FLT3 mutations.
- To underscore the need for targeted FLT3 inhibitor therapies.
Main Methods:
- Review of existing literature on FLT3 mutations in AML.
- Analysis of large-scale studies correlating FLT3 mutations with clinical outcomes.
- Discussion of the molecular mechanisms underlying FLT3-driven leukemogenesis.
Main Results:
- FLT3 mutations are the most frequent genetic alterations in AML.
- FLT3/ITD mutations are associated with leukocytosis and a poor prognosis.
- Standard treatments like chemotherapy and stem cell transplantation are less effective in the presence of FLT3 mutations.
Conclusions:
- Routine screening for FLT3 mutations is crucial for AML patient risk stratification.
- FLT3 kinase inhibitors represent a potential therapeutic avenue for AML.
- Targeted therapies are needed to overcome the adverse prognostic impact of FLT3 mutations in AML.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase